-
公开(公告)号：US20150344583A1
公开(公告)日：2015-12-03
申请号：US14649469
申请日：2013-12-05
Applicant: AMGEN INC.
Inventor： Richard J. ARMITAGE , Michelle BLAKE , William C. FANSLOW, III , Jason Charles O'NEILL , Gunasekaran KANNAN , Jiangchun XU , Mark Edward TOMETSKO , Zhulun WANG , Athena SUDOM
CPC classification number: C07K16/2878 , A61K45/06 , A61K47/6803 , A61K47/6849 , A61K2039/505 , A61N5/10 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94
Abstract: The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates and uses thereof.
Abstract translation: 本发明涉及BCMA（B细胞成熟抗原）抗原结合蛋白，例如抗体，编码所述抗原结合蛋白的多核苷酸序列，以及用于诊断和治疗疾病的组合物和方法。 本发明还涉及BCMA抗体药物共轭物及其用途。
-
公开(公告)号：US20180237542A1
公开(公告)日：2018-08-23
申请号：US15922778
申请日：2016-09-15
Applicant: AMGEN INC.
Inventor： Gunasekaran KANNAN , Michelle HORTTER , Edward J. BELOUSKI
CPC classification number: C07K16/468 , C07K16/00 , C07K16/241 , C07K16/2875 , C07K2317/14 , C07K2317/31 , C07K2317/35 , C07K2317/522 , C07K2317/56 , C07K2317/66 , C07K2317/90
Abstract: The present invention relates to tetravalent bispecific and tetraspecific antigen binding proteins that are capable of binding to multiple targets. Pharmaceutical compositions comprising the bispecific and tetraspecific antigen binding proteins as well as methods for producing them are also disclosed.
-
公开(公告)号：US20180237489A1
公开(公告)日：2018-08-23
申请号：US15893451
申请日：2018-02-09
Applicant: AMGEN INC.
Inventor： Gunasekaran KANNAN
Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
-
公开(公告)号：US20170137485A1
公开(公告)日：2017-05-18
申请号：US15408281
申请日：2017-01-17
Applicant: Amgen Inc.
Inventor： Marc A. GAVIN , Gunasekaran KANNAN , Li LI , Joshua T. PEARSON , Margaret KAROW
IPC: C07K14/55
CPC classification number: C07K14/55 , A61K38/00 , C07K16/00 , C07K2317/41 , C07K2317/52 , C07K2317/524 , C07K2317/71 , C07K2317/94 , C07K2319/21 , C07K2319/30 , C07K2319/43
Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
-
公开(公告)号：US20170081382A1
公开(公告)日：2017-03-23
申请号：US15371131
申请日：2016-12-06
Applicant: Amgen Inc.
Inventor： Gunasekaran KANNAN
CPC classification number: C07K14/55 , A61K38/00 , C07K16/00 , C07K2317/41 , C07K2317/52 , C07K2317/524 , C07K2317/71 , C07K2317/94 , C07K2319/21 , C07K2319/30 , C07K2319/43
Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
-
Patent Agency Ranking
公开(公告)号：US20160193295A1
公开(公告)日：2016-07-07
申请号：US14909431
申请日：2014-07-30
Applicant: AMGEN INC.
Inventor： Gunasekaran KANNAN , Jennifer LAVALLEE , Frederick W. JACOBSEN
IPC: A61K38/18 , A61K47/48 , C07K14/475
CPC classification number: A61K38/18 , A61K47/48376 , A61K47/6801 , C07K14/475 , C07K16/00 , C07K2317/52 , C07K2317/526 , C07K2319/30
Abstract: This disclosure provides polypeptides comprising an antibody Fc region having a deletion of one or more cysteine residues in the hinge region and substitution with a sulfhydryl-containing residue of one or more CH3-interface amino acids. Also, provided are Fc-fusion proteins and antibodies containing said polypeptides, nucleic acids and vectors encoding said polypeptides, along with host cells and methods for making said polypeptides.
Abstract translation: 本公开提供了包含在铰链区中具有一个或多个半胱氨酸残基缺失的抗体Fc区并用一个或多个CH 3界面氨基酸的含巯基残基取代的多肽。 此外，提供了Fc融合蛋白和含有所述多肽，核酸和编码所述多肽的载体以及宿主细胞的Fc融合蛋白和制备所述多肽的方法。
-
公开(公告)号：US20220213226A1
公开(公告)日：2022-07-07
申请号：US17379968
申请日：2021-07-19
Applicant: AMGEN INC.
Inventor： Hailing HSU , Gunasekaran KANNAN , Kenneth W. WALKER , Michelle HORTTER , Edward J. BELOUSKI
IPC: C07K16/46 , C07K16/24 , C07K16/28 , A61K39/395
Abstract: The present invention concerns antigen binding proteins that bind TL1A, including bispecific antigen binding proteins (e.g., antibodies) to TL1A and TNF-α. Such bispecific antibodies can be in a tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the antibody is directed to TL1A and the other to TNF-α. The bispecific antigen binding proteins may also be comprised in an IgG-scFv fusion, in which a conventional tetrameric antibody directed to one antigen is fused to a pair of single chain Fv units directed to the other. The bispecific antigen binding protein may also be comprised in an IgG-Fab fusion, in which a Fab molecule that binds to one antigen is fused to each heavy chain of a conventional tetrameric antibody directed to the other antigen. The invention further relates to uses of the anti-TL1A binding proteins and anti-TL1A/anti-TNF-α antigen binding proteins, and pharmaceutical formulations thereof.
-
公开(公告)号：US20210139554A1
公开(公告)日：2021-05-13
申请号：US17065395
申请日：2020-10-07
Applicant: Amgen Inc.
Inventor： Eric Alan BUTZ , Christy Ann THOMSON , Marc Alain GAVIN , Ian Nevin FOLTZ , Dong XIA , Dina N. ALCORN , Randal Robert KETCHEM , Ai Ching LIM , Kathy MANCHULENKO , Laura SEKIROV , Kelly Ann BERRY , Cyr Clovis Chua DE IMUS , Neeraj Jagdish AGRAWAL , Gunasekaran KANNAN , Li LI
Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
-
公开(公告)号：US20190315822A1
公开(公告)日：2019-10-17
申请号：US16416050
申请日：2019-05-17
Applicant: Amgen Inc.
Inventor： Yumei XIONG , Yi ZHANG , Jackie Z. SHENG , Agnes Eva HAMBURGER , Murielle M. VENIANT-ELLISON , Grant SHIMAMOTO , Xiaoshan MIN , Zhulun WANG , Jie TANG , Gunasekaran KANNAN , Kenneth W. WALKER , Bryan LEMON
IPC: C07K14/475 , A61K38/00 , C07K14/51 , A61K39/00 , A61K38/17 , A61K38/18 , C07K14/495 , A61K38/16
Abstract: GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
-
20.发明申请公开(公告)号：US20190248906A1
公开(公告)日：2019-08-15
申请号：US16282834
申请日：2019-02-22
Applicant: Amgen, Inc.
Inventor： Yang LI , Jennitte LeAnn STEVENS , Chadwick Terence KING , Ian Nevin FOLTZ , Gunasekaran KANNAN , Junming YIE , Shaw-Fen Sylvia HU
CPC classification number: C07K16/2863 , A61K2039/505 , C07K14/71 , C07K16/40 , C07K2317/21 , C07K2317/31 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/75 , C07K2319/00 , C07K2319/30 , C12Y302/01031
Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing B-Klotho, and or FGF21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.
-
-
-
-
-
-
-
-
-
Search Results
36
records
(took 0.033 seconds)
